Ligand terminates Viking Therapeutics license over alleged breach, Viking disputes

Filed April 30, 2026 · Period ending April 24, 2026 · ~1 min read

Key Changes

• high

  Ligand terminated Viking's license to TR-Beta drug programs (VK2809, VK0214) effective May 4, 2026, alleging Viking failed to use commercially reasonable efforts to develop and commercialize the assets.

  Item 1.01 view on EDGAR →
• high

  Viking is disputing the termination's validity, creating legal uncertainty that could delay Ligand's ability to reclaim or re-partner the TR-Beta assets through arbitration or litigation.

  Item 1.01 view on EDGAR →
• medium

  Upon termination, Viking must grant Ligand a non-exclusive worldwide license to any technology Viking developed for TR-Beta, with Ligand paying low single-digit royalties on future sales.

  Item 1.01 view on EDGAR →